Chemical modification of the M1 agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode

ACS Chemical Neuroscience

Volumn 3, Issue 12, 2012, Pages 1025-1036

  Digby, Gregory J ^a   Utley, Thomas J ^a   Lamsal, Atin ^a   Sevel, Christian ^a   Sheffler, Douglas J ^a   Lebois, Evan P ^a,b   Bridges, Thomas M ^a,b   Wood, Michael R ^a,b,c   Niswender, Colleen M ^a,b   Lindsley, Craig W ^a,b,c   Conn, P Jeffrey ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Acetylcholine; agonist; allosteric; antagonist; GPCR; orthosteric

Indexed keywords

ATROPINE; CALCIUM; CARBACHOL; METHYLSCOPOLAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M1 RECEPTOR ANTAGONIST; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; RADIOLIGAND; RECEPTOR RESERVE; UNCLASSIFIED DRUG; VU 0255035; VU 0357017; VU 0364572; VU 0409774; VU 0409775;

ARTICLE; BINDING SITE; CELL LINE; CHEMICAL MODIFICATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; BENZAMIDES; BIPHENYL COMPOUNDS; CHO CELLS; CRICETINAE; LIGANDS; MUSCARINIC AGONISTS; RATS; RECEPTOR, MUSCARINIC M1;

RATTUS;

EID: 84871313995     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn300103e     Document Type: Article

References (41)

1. Caulfield, M. P. (1993) Muscarinic receptors-characterization, coupling and function Pharmacol. Ther. 58, 319-379 (Pubitemid 23273186)
2. Langmead, C. J., Watson, J., and Reavill, C. (2008) Muscarinic acetylcholine receptors as CNS drug targets Pharmacol. Ther. 117, 232-243
3. Wess, J. (1996) Molecular biology of muscarinic acetylcholine receptors Crit Rev Neurobiol 10, 69-99 (Pubitemid 26283956)
4. Felder, C. C., Bymaster, F. P., Ward, J., and DeLapp, N. (2000) Therapeutic opportunities for muscarinic receptors in the central nervous system J. Med. Chem. 43, 4333-4353 (Pubitemid 32046857)
5. Auld, D. S., Kornecook, T. J., Bastianetto, S., and Quirion, R. (2002) Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies Prog. Neurobiol. 68, 209-245 (Pubitemid 35346805)
6. Chambon, C., Wegener, N., Gravius, A., and Danysz, W. (2011) A new automated method to assess the rat recognition memory: validation of the method Behav Brain Res 222, 151-157
7. Digby, G. J., Noetzel, M. J., Bubser, M., Utley, T. J., Walker, A. G., Byun, N. E., Lebois, E. P., Xiang, Z., Sheffler, D. J., Cho, H. P., Davis, A. A., Nemirovsky, N. E., Mennenga, S. E., Camp, B. W., Bimonte-Nelson, H. A., Bode, J., Italiano, K., Morrison, R., Daniels, J. S., Niswender, C. M., Olive, M. F., Lindsley, C. W., Jones, C. K., and Conn, P. J. (2012) Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models J. Neurosci. 32, 8532-8544
8. Shirey, J. K., Brady, A. E., Jones, P. J., Davis, A. A., Bridges, T. M., Kennedy, J. P., Jadhav, S. B., Menon, U. N., Xiang, Z., Watson, M. L., Christian, E. P., Doherty, J. J., Quirk, M. C., Snyder, D. H., Lah, J. J., Levey, A. I., Nicolle, M. M., Lindsley, C. W., and Conn, P. J. (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning J. Neurosci. 29, 14271-14286
9. Hamilton, S. E., Loose, M. D., Qi, M., Levey, A. I., Hille, B., McKnight, G. S., Idzerda, R. L., and Nathanson, N. M. (1997) Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice Proc. Natl. Acad. Sci. U.S.A. 94, 13311-13316 (Pubitemid 27518518)
10. Pisani, A., Bernardi, G., Ding, J., and Surmeier, D. J. (2007) Re-emergence of striatal cholinergic interneurons in movement disorders Trends Neurosci. 30, 545-553 (Pubitemid 47513239)
11. Sheffler, D. J., Williams, R., Bridges, T. M., Xiang, Z., Kane, A. S., Byun, N. E., Jadhav, S., Mock, M. M., Zheng, F., Lewis, L. M., Jones, C. K., Niswender, C. M., Weaver, C. D., Lindsley, C. W., and Conn, P. J. (2009) A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning Mol. Pharmacol. 76, 356-368
12. Conn, P. J., Jones, C. K., and Lindsley, C. W. (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol. Sci. 30, 148-155
13. Jones, C. K., Brady, A. E., Davis, A. A., Xiang, Z., Bubser, M., Tantawy, M. N., Kane, A. S., Bridges, T. M., Kennedy, J. P., Bradley, S. R., Peterson, T. E., Ansari, M. S., Baldwin, R. M., Kessler, R. M., Deutch, A. Y., Lah, J. J., Levey, A. I., Lindsley, C. W., and Conn, P. J. (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 28, 10422-10433
14. Langmead, C. J., Austin, N. E., Branch, C. L., Brown, J. T., Buchanan, K. A., Davies, C. H., Forbes, I. T., Fry, V. A., Hagan, J. J., Herdon, H. J., Jones, G. A., Jeggo, R., Kew, J. N., Mazzali, A., Melarange, R., Patel, N., Pardoe, J., Randall, A. D., Roberts, C., Roopun, A., Starr, K. R., Teriakidis, A., Wood, M. D., Whittington, M., Wu, Z., and Watson, J. (2008) Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1 Br. J. Pharmacol. 154, 1104-1115 (Pubitemid 351915055)
15. Spalding, T. A., Trotter, C., Skjaerbaek, N., Messier, T. L., Currier, E. A., Burstein, E. S., Li, D., Hacksell, U., and Brann, M. R. (2002) Discovery of an ectopic activation site on the M(1) muscarinic receptor Mol. Pharmacol. 61, 1297-1302 (Pubitemid 34575739)
16. 1 Agonist Derived from the MLPCN Probe ML071 Bioorg. Med. Chem. Lett. 21, 6451-6455
17. Lebois, E. P., Bridges, T. M., and Lewis, L. M. 2009, Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M1 Receptor Function in the Central Nervous System ACS Chem. Neurosci. 1, 104-121
18. Melancon, B. J., Hopkins, C. R., Wood, M. R., Emmitte, K. A., Niswender, C. M., Christopoulos, A., Conn, P. J., and Lindsley, C. W. (2012) Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery J. Med. Chem. 55, 1445-1464
19. Avlani, V. A., Langmead, C. J., Guida, E., Wood, M. D., Tehan, B. G., Herdon, H. J., Watson, J. M., Sexton, P. M., and Christopoulos, A. (2010) Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor Mol. Pharmacol. 78, 94-104
20. Conklin, B. R., Farfel, Z., Lustig, K. D., Julius, D., and Bourne, H. R. (1993) Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha Nature 363, 274-276 (Pubitemid 23158533)
21. Lazareno, S. and Birdsall, N. J. (1993) Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations Br. J. Pharmacol. 109, 1110-1119 (Pubitemid 23216780)
22. Bymaster, F. P. and Falcone, J. F. (2000) Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium Eur. J. Pharmacol. 390, 245-248 (Pubitemid 30119938)
23. Arunlakshana, O. and Schild, H. O. (1959) Some quantitative uses of drug antagonists Br. J. Pharmacol. Chemother. 14, 48-58
24. Kim, M. G., Bodor, E. T., Wang, C., Harden, T. K., and Kohn, H. (2003) C(8) substituted 1-azabicyclo[3.3.1]non-3-enes and C(8) substituted 1-azabicyclo[3.3.1]nonan-4-ones: novel muscarinic receptor antagonists J. Med. Chem. 46, 2216-2226 (Pubitemid 36583500)
25. Besse, J. C. and Furchgott, R. F. (1976) Dissociation constants and relative efficacies of agonists acting on alpha adrenergic receptors in rabbit aorta J. Pharmacol. Exp. Ther. 197, 66-78
26. Furchgott, R. (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes, Academic Press, London.
27. Black, J. W. and Leff, P. (1983) Operational models of pharmacological agonism Proc. R. Soc. London, Ser. B 220, 141-162 (Pubitemid 14217337)
28. Christopoulos, A., Parsons, A. M., Lew, M. J., and El-Fakahany, E. E. (1999) The assessment of antagonist potency under conditions of transient response kinetics Eur. J. Pharmacol. 382, 217-227 (Pubitemid 29509837)
29. Jacobson, M. A., Kreatsoulas, C., Pascarella, D. M., O'Brien, J. A., and Sur, C. (2010) The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1′-(2-methylbenzyl)-1,4′-bipiperidin-4-yl]-1,3-dihydro-2H- benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site Mol. Pharmacol. 78, 648-657
30. Digby, G. J., Shirey, J. K., and Conn, P. J. (2010) Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders Mol. Biosyst. 6, 1345-1354
31. Kuduk, S. D., Chang, R. K., Di Marco, C. N., Pitts, D. R., Greshock, T. J., Ma, L., Wittmann, M., Seager, M. A., Koeplinger, K. A., Thompson, C. D., Hartman, G. D., Bilodeau, M. T., and Ray, W. J. (2011) Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold J. Med. Chem. 54, 4773-4780
32. Kuduk, S. D., Chang, R. K., Di Marco, C. N., Ray, W. J., Ma, L., Wittmann, M., Seager, M. A., Koeplinger, K. A., Thompson, C. D., Hartman, G. D., and Bilodeau, M. T. (2011) Quinolizidinone carboxylic acid selective M1 allosteric modulators: SAR in the piperidine series Bioorg. Med. Chem. Lett. 21, 1710-1715
33. Ma, L., Seager, M. A., Wittmann, M., Jacobson, M., Bickel, D., Burno, M., Jones, K., Graufelds, V. K., Xu, G., Pearson, M., McCampbell, A., Gaspar, R., Shughrue, P., Danziger, A., Regan, C., Flick, R., Pascarella, D., Garson, S., Doran, S., Kreatsoulas, C., Veng, L., Lindsley, C. W., Shipe, W., Kuduk, S., Sur, C., Kinney, G., Seabrook, G. R., and Ray, W. J. (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation Proc. Natl. Acad. Sci. U.S.A. 106, 15950-15955
34. Marlo, J. E., Niswender, C. M., Days, E. L., Bridges, T. M., Xiang, Y., Rodriguez, A. L., Shirey, J. K., Brady, A. E., Nalywajko, T., Luo, Q., Austin, C. A., Williams, M. B., Kim, K., Williams, R., Orton, D., Brown, H. A., Lindsley, C. W., Weaver, C. D., and Conn, P. J. (2009) Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity Mol. Pharmacol. 75, 577-588
35. Reid, P. R., Bridges, T. M., Sheffler, D. J., Cho, H. P., Lewis, L. M., Days, E., Daniels, J. S., Jones, C. K., Niswender, C. M., Weaver, C. D., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2011) Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe Bioorg. Med. Chem. Lett. 21, 2697-2701
36. Xiang, Z., T. A. D., Jones, C. K., Lindsley, C. W., and Conn, P. J. (2012) Roles of M1 muscarinic acetylcholine receptor subtype in regulation of basal ganglia function and implications for treatment of Parkinson's disease J. Pharmacol. Exp. Ther. 340 (3) 595-603
37. Langmead, C. J., Fry, V. A., Forbes, I. T., Branch, C. L., Christopoulos, A., Wood, M. D., and Herdon, H. J. (2006) Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist Mol. Pharmacol. 69, 236-246 (Pubitemid 43048910)
38. Melancon, B. J., Gogliotti, R. D., Tarr, J. C., Saleh, S. A., Chauder, B. A., Lebois, E. P., Cho, H. P., Utley, T. J., Sheffler, D. J., Bridges, T. M., Morrison, R. D., Daniels, J. S., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2012) Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM(1) muscarinic acetylcholine receptor Bioorg. Med. Chem. Lett. 22, 3467-3472
39. Valant, C., Gregory, K. J., Hall, N. E., Scammells, P. J., Lew, M. J., Sexton, P. M., and Christopoulos, A. (2008) A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand J. Biol. Chem. 283, 29312-29321
40. Noetzel, M. J., Rook, J. M., Vinson, P. N., Cho, H. P., Days, E., Zhou, Y., Rodriguez, A. L., Lavreysen, H., Stauffer, S. R., Niswender, C. M., Xiang, Z., Daniels, J. S., Jones, C. K., Lindsley, C. W., Weaver, C. D., and Conn, P. J. (2012) Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function Mol. Pharmacol. 81, 120-133
41. Wood, M. R., Hopkins, C. R., Brogan, J. T., Conn, P. J., and Lindsley, C. W. (2011) Molecular switches on mGluR allosteric ligands that modulate modes of pharmacology Biochemistry 50, 2403-2410